Literature DB >> 15057662

Pirfenidone.

Joseph Lasky1.   

Abstract

Pirfenidone, an antifibrotic tissue growth antagonist, is in development for the potential treatment of fibrotic diseases including renal, liver and pulmonary fibrosis and for multiple sclerosis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15057662

Source DB:  PubMed          Journal:  IDrugs        ISSN： 1369-7056


  11 in total

Review 1.  A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays.

Authors:  Phyllis C Leppert; William H Catherino; James H Segars
Journal:  Am J Obstet Gynecol       Date:  2006-04-25       Impact factor: 8.661

2.  Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.

Authors:  Satomi Onoue; Yoshiki Seto; Masashi Kato; Yosuke Aoki; Yoshiki Kojo; Shizuo Yamada
Journal:  Pharm Res       Date:  2013-02-21       Impact factor: 4.200

3.  CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.

Authors:  Aftab Ullah; Kaikai Wang; Pengkai Wu; David Oupicky; Minjie Sun
Journal:  Int J Nanomedicine       Date:  2019-04-26

Review 4.  Myofibroblast differentiation and survival in fibrotic disease.

Authors:  Kornelia Kis; Xiaoqiu Liu; James S Hagood
Journal:  Expert Rev Mol Med       Date:  2011-08-23       Impact factor: 5.600

Review 5.  Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

6.  Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling.

Authors:  Yoshiki Seto; Gen Suzuki; Sharon Shui Yee Leung; Hak-Kim Chan; Satomi Onoue
Journal:  Pharm Res       Date:  2016-03-14       Impact factor: 4.200

7.  Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection.

Authors:  Peyman Bizargity; Kaifeng Liu; Liqing Wang; Wayne W Hancock; Gary A Visner
Journal:  Transplantation       Date:  2012-07-27       Impact factor: 4.939

8.  Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts.

Authors:  Chaoming Zhou; Fang Liu; Phillip H Gallo; Mark E Baratz; Sandeep Kathju; Latha Satish
Journal:  BMC Musculoskelet Disord       Date:  2016-11-11       Impact factor: 2.362

9.  Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium.

Authors:  Yuan Liu; Fuai Lu; Lirong Kang; Zhihua Wang; Yongfu Wang
Journal:  BMC Pulm Med       Date:  2017-04-18       Impact factor: 3.317

10.  Recoverability of renal function after relief of chronic partial unilateral ureteric obstruction: The effect of an angiotensin-converting enzyme inhibitor (enalapril).

Authors:  Shady A Soliman; Ahmed A Shokeir; Ahmed Mosbah; Hassan Abol-Enein; Nashwa Barakat; Essam Abou-Bieh; Ehab W Wafa
Journal:  Arab J Urol       Date:  2011-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.